Abstract
Exogenous growth hormone has different actions depending on the method of administration. However, the effects of different modes of administration of the placental variant of growth hormone on growth, body composition and glucose metabolism have not been investigated. In this study, we examined the effect of pulsatile vs. continuous administration of recombinant variant of growth hormone in a normal mouse model. Female C57BL/6J mice were randomized to receive vehicle or variant of growth hormone (2 or 5 mg/kg per day) by daily subcutaneous injection (pulsatile) or osmotic pump for 6 days. Pulsatile treatment with 2 and 5 mg/kg per day significantly increased body weight. There was also an increase in liver, kidney and spleen weight via pulsatile treatment, whereas continuous treatment did not affect body weight or organ size. Pulsatile treatment with 5 mg/kg per day significantly increased fasting plasma insulin concentration, whereas with continuous treatment, fasting insulin concentration was not significantly different from the vehicle-treated control. However, a dose-dependent increase in fasting insulin concentration and decrease in insulin sensitivity, as assessed by HOMA, was observed with both modes of treatment. At 5 mg/kg per day, hepatic growth hormone receptor expression was increased compared to vehicle-treated animals, by both modes of administration. Pulsatile variant of growth hormone did not alter the plasma insulin-like growth factor-1 concentration, whereas a slight decrease was observed with continuous variant of growth hormone treatment. Neither pulsatile nor continuous treatment affected hepatic insulin-like growth factor-1 mRNA expression. Our findings suggest that pulsatile variant of growth hormone treatment was more effective in stimulating growth but caused marked hyperinsulinemia in mice.
Similar content being viewed by others
References
H. Hirt, J. Kimelman, M.J. Birnbaum, E.Y. Chen, P.H. Seeburg, N.L. Eberhardt, A. Barta, The human growth-hormone gene locus – structure, evolution, and allelic variations. DNA-J Molec Cell Bio 6(1), 59–70 (1987). doi:10.1089/dna.1987.6.59
E. Alsat, J. Guibourdenche, A. Couturier, D. Evain-Brion, Physiological role of human placental growth hormone. Mol Cell Endocrinol 140(1–2), 121–127 (1998)
F. Frankenne, M.L. Scippo, J. Vanbeeumen, A. Igout, G. Hennen, Identification of placental human growth-hormone as the growth hormone-v gene-expression product. J Clin Endocr Metab 71(1), 15–18 (1990)
L. Eriksson, F. Frankenne, S. Eden, G. Hennen, B. Von Schoultz, Growth hormone 24-h serum profiles during pregnancy–lack of pulsatility for the secretion of the placental variant. Brit J Obstet Gynaec 96(8), 949–953 (1989). doi:10.1111/j.1471-0528.1989.tb03352.x
E. Alsat, J. Guibourdenche, D. Luton, F. Frankenne, D. Evain-Brion, Human placental growth hormone. Am J Obstet Gynecol 177(6), 1526–1534 (1997)
J. Verhaeghe, Does the physiological acromegaly of pregnancy benefit the fetus? Gynecol Obstet Invest 66(4), 217–226 (2008). doi:10.1159/000147167
A. Igout, F. Frankenne, M. L’Hermite-Baleriaux, A. Martin, G. Hennen, Somatogenic and lactogenic activity of the recombinant 22 kDa isoform of human placental growth hormone. Growth Regul 5(1), 60–65 (1995)
J.N. MacLeod, I. Worsley, J. Ray, H.G. Friesen, S.A. Liebhaber, N.E. Cooke, Human growth hormone-variant is a biologically active somatogen and lactogen. Endocrinology 128(3), 1298–1302 (1991). doi:10.1210/endo-128-3-1298
M. Chellakooty, K. Vangsgaard, T. Larsen, T. Scheike, J. Falck-Larsen, J. Legarth, A.M. Andersson, K.M. Main, N.E. Skakkebaek, A. Juul, A longitudinal study of intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth. J Clin Endocrinol Metab 89(1), 384–391 (2004). doi:10.1210/jc.2003-030282
H.D. McIntyre, R. Serek, D.I. Crane, T. Veveris-Lowe, A. Parry, S. Johnson, K.C. Leung, K.K. Ho, M. Bougoussa, G. Hennen, A. Igout, F.Y. Chan, D. Cowley, A. Cotterill, R. Barnard, Placental growth hormone (GH), GH-binding protein, and insulin-like growth factor axis in normal, growth-retarded, and diabetic pregnancies: correlations with fetal growth. J Clin Endocrinol Metab 85(3), 1143–1150 (2000). doi:10.1210/jcem.85.3.6480
V. Mirlesse, F. Frankenne, E. Alsat, M. Poncelet, G. Hennen, D. Evain-Brion, Placental growth hormone levels in normal pregnancy and in pregnancies with intrauterine growth retardation. Pediatr Res 34(4), 439–442 (1993). doi:10.1203/00006450-199310000-00012
M. Koutsaki, S. Sifakis, A. Zaravinos, D. Koutroulakis, O. Koukoura, D.A. Spandidos, Decreased placental expression of hPGH, IGF-I and IGFBP-1 in pregnancies complicated by fetal growth restriction. Growth Horm IGF Res 21(1), 31–36 (2011). doi:10.1016/j.ghir.2010.12.002
A. Caufriez, F. Frankenne, Y. Englert, J. Golstein, F. Cantraine, G. Hennen, G. Copinschi, Placental Growth-Hormone as a Potential Regulator of Maternal Igf-I during Human-Pregnancy. Am J Physiol 258(6), E1014–E1019 (1990)
R.G. Clark, J.O. Jansson, O. Isaksson, I.C. Robinson, Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J Endocrinol 104(1), 53–61 (1985)
J. Isgaard, L. Carlsson, O.G. Isaksson, J.O. Jansson, Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology 123(6), 2605–2610 (1988). doi:10.1210/endo-123-6-2605
M.J. Azain, T.J. Roberts, R.J. Martin, T.R. Kasser, Comparison of daily versus continuous administration of somatotropin on growth rate, feed intake, and body composition in intact female rats. J Anim Sci 73(4), 1019–1029 (1995)
M.J. Azain, T.R. Kasser, M.J. Sabacky, C.A. Baile, Comparison of the growth-promoting properties of daily versus continuous administration of somatotropin in female rats with intact pituitaries. J Anim Sci 71(2), 384–392 (1993)
J. Oscarsson, M. Ottosson, J.O. Johansson, O. Wiklund, P. Marin, P. Bjorntorp, B.A. Bengtsson, Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity. Metab Clin Exp 45(3), 370–377 (1996)
R.F. Selden, T.E. Wagner, S. Blethen, J.S. Yun, M.E. Rowe, H.M. Goodman, Expression of the human growth hormone variant gene in cultured fibroblasts and transgenic mice. P Natl Acad Sci 85(21), 8241–8245 (1988)
L.A. Barbour, J. Shao, L. Qiao, L.K. Pulawa, D.R. Jensen, A. Bartke, M. Garrity, B. Draznin, J.E. Friedman, Human placental growth hormone causes severe insulin resistance in transgenic mice. Am J Obstet Gynecol 186(3), 512–517 (2002)
G. Solomon, S. Reicher, E.E. Gussakovsky, J.B. Jomain, A. Gertler, Large-scale preparation and in vitro characterization of biologically active human placental (20 and 22K) and pituitary (20K) growth hormones: placental growth hormones have no lactogenic activity in humans. Growth Horm IGF Res 16(5-6), 297–307 (2006). doi:10.1016/j.ghir.2006.07.002
D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment - insulin resistance and beta-cell function from fasting plasma-glucose and insulin concentrations in man. Diabetologia 28(7), 412–419 (1985). doi:10.1007/Bf00280883
T.D. Schmittgen, K.J. Livak, Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6), 1101–1108 (2008)
R.A. Frost, G.J. Nystrom, C.H. Lang, Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts. Endocrinology 143(2), 492–503 (2002). doi:10.1210/endo.143.2.8641
M. Imanaka, K. Iida, A. Murawaki, H. Nishizawa, H. Fukuoka, R. Takeno, Y. Takahashi, Y. Okimura, H. Kaji, K. Chihara, Growth hormone stimulates mechano growth factor expression and activates myoblast transformation in C2C12 cells. Kobe J Med Sci 54(1), E46–54 (2008)
T. Laursen, B. Grandjean, J.O. Jorgensen, J.S. Christiansen, Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration. Euro J Endocrinol 135(3), 309–315 (1996)
V. Roelfsema, G.B. Thomas, H. Lin, B.H. Breier, L. Maxwell, M.H. Oliver, E. Heineman, R.G. Clark, P.D. Gluckman, The metabolic effects of endotoxin are differentially affected by the pattern of GH administration in the rat. J Endocrinol 171(1), 173–181 (2001)
C.A. Jaffe, B. Ocampo-Lim, W. Guo, K. Krueger, I. Sugahara, R. DeMott-Friberg, M. Bermann, A.L. Barkan, Regulatory mechanisms of growth hormone secretion are sexually dimorphic. J Clin Invest 102(1), 153–164 (1998). doi:10.1172/jci2908
J.N. MacLeod, N.A. Pampori, B.H. Shapiro, Sex differences in the ultradian pattern of plasma growth hormone concentrations in mice. J Endocrinol 131(3), 395–399 (1991)
J.O. Jansson, S. Eden, O. Isaksson, Sexual dimorphism in the control of growth hormone secretion. Endocr Rev 6(2), 128–150 (1985). doi:10.1210/edrv-6-2-128
S. Eden, Age- and sex-related differences in episodic growth hormone secretion in the rat. Endocrinology 105(2), 555–560 (1979). doi:10.1210/endo-105-2-555
J.O. Jansson, K. Albertsson-Wikland, S. Eden, K.G. Thorngren, O. Isaksson, Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats. Acta Physiologica Scandinavica 114(2), 261–265 (1982). doi:10.1111/j.1748-1716.1982.tb06980.x
K.G. Thorngren, L.I. Hansson, Effect of administration frequency of growth hormone on longitudinal bone growth in the hypophysectomized rat. Acta Endocrinologica 84(3), 497–511 (1977)
D. Maiter, L.E. Underwood, M. Maes, M.L. Davenport, J.M. Ketelslegers, Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C/insulin-like growth factor I and liver GH receptors in hypophysectomized rats. Endocrinology 123(2), 1053–1059 (1988). doi:10.1210/endo-123-2-1053
R.G. Clark, D. Mortensen, L.M. Carlsson, D. Carmignac, I. Robinson, Growth responses to patterned GH delivery. Endocrine 3(10), 717–723 (1995). doi:10.1007/bf03000203
J.J. Kopchick, J.M. Andry, Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab 71(1-2), 293–314 (2000). doi:10.1006/mgme.2000.3068
A. Caufriez, F. Frankenne, G. Hennen, G. Copinschi, Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265(4 Pt 1), E572–577 (1993)
S. Handwerger, M. Freemark, The roles of placental growth hormone and placental lactogen in the regulation of human fetal growth and development. J Pediatr Endocrinol Metab 13(4), 343–356 (2000)
E.M. Naar, A. Bartke, S.S. Majumdar, F.C. Buonomo, J.S. Yun, T.E. Wagner, Fertility of transgenic female mice expressing bovine growth hormone or human growth hormone variant genes. Biol Reprod 45(1), 178–187 (1991)
M. Bielohuby, M. Schaab, M. Kummann, M. Sawitzky, R. Gebhardt, G. Binder, J. Frystyk, M. Bjerre, A. Hoeflich, J. Kratzsch, M. Bidlingmaier, Serum IGF-I is not a reliable pharmacodynamic marker of exogenous growth hormone activity in mice. Endocrinology 152(12), 4764–4776 (2011). doi:10.1210/en.2011-1432
T. Bick, Z. Hochberg, T. Amit, O.G. Isaksson, J.O. Jansson, Roles of pulsatility and continuity of growth hormone (GH) administration in the regulation of hepatic GH-receptors, and circulating GH-binding protein and insulin-like growth factor-I. Endocrinology 131(1), 423–429 (1992). doi:10.1210/endo.131.1.1612023
W.R. Baumbach, B. Bingham, One class of growth hormone (GH) receptor and binding protein messenger ribonucleic acid in rat liver, GHR1, is sexually dimorphic and regulated by GH. Endocrinology 136(2), 749–760 (1995). doi:10.1210/endo.136.2.7835307
D.F. Carmignac, I.C. Robinson, B. Enberg, G. Norstedt, Growth hormone receptor regulation in growth hormone-deficient dwarf rats. J Endocrinol 138(2), 267–274 (1993)
D.F. Carmignac, T. Wells, L.M. Carlsson, R.G. Clark, I.C. Robinson, Growth hormone (GH)-binding protein in normal and GH-deficient dwarf rats. J Endocrinol 135(3), 447–457 (1992)
L. Gonzalez, A.I. Sotelo, A. Bartke, D. Turyn, Up-regulation of GH-binding protein by mouse GH in transgenic mice overexpressing GH-releasing hormone. J Endocrinol 163(2), 299–307 (1999)
A. Edens, J.N. Southard, F. Talamantes, Mouse growth hormone-binding protein and growth hormone receptor transcripts are produced from a single gene by alternative splicing. Endocrinology 135(6), 2802–2805 (1994). doi:10.1210/endo.135.6.7988474
F. Talamantes, R. Ortiz, Structure and regulation of expression of the mouse GH receptor. J Endocrinol 175(1), 55–59 (2002)
F. Sanchez-Jimenez, P.J. Fielder, R.R. Martinez, W.C. Smith, F. Talamantes, Hypophysectomy eliminates and growth hormone (GH) maintains the midpregnancy elevation in GH receptor and serum binding protein in the mouse. Endocrinology 126(2), 1270–1275 (1990). doi:10.1210/endo-126-2-1270
R.J. Cerio, F. Xing, R.J. Fatula, D.E. Keith, X. Yang, F. Talamantes, J.N. Southard, J.N. Southard, Structurally distinct membrane-associated and soluble forms of GH-binding protein in the mouse. J Endocrinol 172(2), 321–331 (2002)
L. Gonzalez, L.M. Curto, J.G. Miquet, A. Bartke, D. Turyn, A.I. Sotelo, Differential regulation of membrane associated-growth hormone binding protein (MA-GHBP) and growth hormone receptor (GHR) expression by growth hormone (GH) in mouse liver. Growth Horm IGF Res 17(2), 104–112 (2007). doi:10.1016/j.ghir.2006.12.002
R.C. Baxter, Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab 67(2), 265–272 (1988). doi:10.1210/jcem-67-2-265
G.T. Ooi, F.J. Cohen, L.Y.-H. Tseng, M.M. Rechler, Y.R. Boisclair, Growth hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the circulating insulin-like growth factor-binding protein complex and ALS promoter activity in rat liver. Mol Endocrinol 11(7), 997–1007 (1997)
C. Carter-Su, J. Schwartz, L. Smit, Molecular mechanism of growth hormone action. Annu Rev Physiol 58(1), 187–207 (1996)
J.J. Kopchick, J.M. Andry, Growth hormone (GH), GH receptor, and signal transduction. Mol Gen Metab 71(1), 293–314 (2000)
M. Lacroix, J. Guibourdenche, J. Frendo, F. Muller, D. Evain-Brion, Human placental growth hormone—a review. Placenta 23, S87–S94 (2002)
I. Ueki, G.T. Ooi, M.L. Tremblay, K.R. Hurst, L.A. Bach, Y.R. Boisclair, Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system. Proc Natl Acad Sci 97(12), 6868–6873 (2000)
H.M. Domené, S.V. Bengolea, A.S. Martínez, M.G. Ropelato, P. Pennisi, P. Scaglia, J.J. Heinrich, H.G. Jasper, Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 350(6), 570–577 (2004)
H.M. Goodman, Separation of early and late responses of adipose tissue to growth hormone. Endocrinology 109(1), 120–129 (1981). doi:10.1210/endo-109-1-120
M.B. Davidson, Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 8(2), 115–131 (1987). doi:10.1210/edrv-8-2-115
P. Metcalfe, D.G. Johnston, R. Nosadini, H. Orksov, K.G. Alberti, Metabolic effects of acute and prolonged growth hormone excess in normal and insulin-deficient man. Diabetologia 20(2), 123–128 (1981)
F. Salomon, R.C. Cuneo, R. Hesp, P.H. Sonksen, The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321(26), 1797–1803 (1989). doi:10.1056/nejm198912283212605
J.O. Johansson, J. Oscarsson, R. Bjarnason, B.A. Bengtsson, Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis. Metab Clin Exp 45(3), 362–369 (1996)
T. Laursen, J.O. Jorgensen, G. Jakobsen, B.L. Hansen, J.S. Christiansen, Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. J Clin Endocrinol Metab 80(8), 2410–2418 (1995). doi:10.1210/jcem.80.8.7543114
H.M. Goodman, L.R. Tai, J. Ray, N.E. Cooke, S.A. Liebhaber, Human growth hormone variant produces insulin-like and lipolytic responses in rat adipose tissue. Endocrinology 129(4), 1779–1783 (1991). doi:10.1210/endo-129-4-1779
J. Xu, J.L. Messina, Crosstalk between growth hormone and insulin signaling. Vitam Horm 80, 125–153 (2009). doi:10.1016/S0083-6729(08)00606-7
C. Carter-Su, J. Schwartz, L.S. Smit, Molecular mechanism of growth hormone action. Annu Rev Physiol 58(1), 187–207 (1996). doi:10.1146/annurev.ph.58.030196.001155
F.P. Dominici, D. Turyn, Growth hormone-induced alterations in the insulin-signaling system. Exp Biol Med 227(3), 149–157 (2002)
J.A. Costoya, J. Finidori, S. Moutoussamy, R. Searis, J. Devesa, V.M. Arce, Activation of growth hormone receptor delivers an antiapoptotic signal: evidence for a role of Akt in this pathway. Endocrinology 140(12), 5937–5943 (1999). doi:10.1210/endo.140.12.7209
R.R. Prattali, G.C. Barreiro, C.T. Caliseo, F.Y. Fugiwara, M. Ueno, P.O. Prada, L.A. Velloso, M.J. Saad, J.B. Carvalheira, Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in growth hormone treated animals. FEBS Lett 579(14), 3152–3158 (2005). doi:10.1016/j.febslet.2005.04.075
F.P. Dominici, D.P. Argentino, M.C. Munoz, J.G. Miquet, A.I. Sotelo, D. Turyn, Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 15(5), 324–336 (2005). doi:10.1016/j.ghir.2005.07.001
T. Laursen, C.H. Gravholt, L. Heickendorff, J. Drustrup, A.M. Kappelgaard, J.O. Jorgensen, J.S. Christiansen, Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab 86(3), 1222–1228 (2001). doi:10.1210/jcem.86.3.7323
L.A. Barbour, J. Shao, L. Qiao, W. Leitner, M. Anderson, J.E. Friedman, B. Draznin, Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinology 145(3), 1144–1150 (2004). doi:10.1210/en.2003-1297
J.P. del Rincon, K. Iida, B.D. Gaylinn, C.E. McCurdy, J.W. Leitner, L.A. Barbour, J.J. Kopchick, J.E. Friedman, B. Draznin, M.O. Thorner, Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 56(6), 1638–1646 (2007). doi:10.2337/db06-0299
H. Cho, J.L. Thorvaldsen, Q. Chu, F. Feng, M.J. Birnbaum, Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276(42), 38349–38352 (2001)
H. Cho, J. Mu, J.K. Kim, J.L. Thorvaldsen, Q. Chu, E.B. Crenshaw, K.H. Kaestner, M.S. Bartolomei, G.I. Shulman, M.J. Birnbaum, Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292(5522), 1728–1731 (2001)
S. Liao, M.H. Vickers, J.L. Stanley, A.P. Ponnampalam, P.N. Baker, J.K. Perry, The placental variant of human growth hormone reduces maternal insulin sensitivity in a dose-dependent manner in C57BL/6J mice. Endocrinology 157(3), 1175–1186 (2016). doi:10.1210/en.2015-1718
E.D. Abel, O. Peroni, J.K. Kim, Y.B. Kim, O. Boss, E. Hadro, T. Minnemann, G.I. Shulman, B.B. Kahn, Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409(6821), 729–733 (2001). doi:10.1038/35055575
A. Zisman, O.D. Peroni, E.D. Abel, M.D. Michael, F. Mauvais-Jarvis, B.B. Lowell, J.F. Wojtaszewski, M.F. Hirshman, A. Virkamaki, L.J. Goodyear, C.R. Kahn, B.B. Kahn, Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 6(8), 924–928 (2000). doi:10.1038/78693
W.T. Garvey, L. Maianu, J.H. Zhu, G. Brechtel-Hook, P. Wallace, A.D. Baron, Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest 101(11), 2377–2386 (1998). doi:10.1172/jci1557
P.R. Shepherd, B.B. Kahn, Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. N Engl J Med 341(4), 248–257 (1999). doi:10.1056/NEJM199907223410406
A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9(5), 367–377 (2008). doi:10.1038/nrm2391
R. Clark, L.M.S. Carlsson, I. Robinson, Growth hormone (GH) secretion in the conscious rat: negative feedback of GH on its own release. J Endocrinol 119(2), 201–209 (1988)
Acknowledgements
This work was funded by Gravida: National Centre for Growth and Development (NZ).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Liao, S., Vickers, M.H., Evans, A. et al. Comparison of pulsatile vs. continuous administration of human placental growth hormone in female C57BL/6J mice. Endocrine 54, 169–181 (2016). https://doi.org/10.1007/s12020-016-1060-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-1060-0